RGDXQ (Response Genetics) Net Income From Continuing Operations: $-15.91 Mil (TTM As of Jun. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Response Genetics Net Income From Continuing Operations?

Response Genetics RGDXQ -99.00% Net Income From Continuing Operations is $-15.91 Mil as of Jun. 2015.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Response Genetics's net income from continuing operations for the three months ended in Jun. 2015 was $-4.83 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2015 was $-15.91 Mil.

Response Genetics Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Response Genetics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Net Income From Continuing Operations Chart

Response Genetics Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.67 -5.70 -7.76 -8.02 -13.70

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.14 -3.64 -3.41 -4.02 -4.83

Response Genetics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-15.91 Mil mean?
Response Genetics (RGDXQ) has a Net Income From Continuing Operations of $-15.91 Mil as of Jun. 2015. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Response Genetics and its competitors.
Is Response Genetics' Net Income From Continuing Operations too high?
Response Genetics' current Net Income From Continuing Operations is $-15.91 Mil.
How does Response Genetics' Net Income From Continuing Operations compare to PSID and GBSN?
Response Genetics' Net Income From Continuing Operations of $-15.91 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Diagnostics & Research company?
A good Net Income From Continuing Operations depends on the Medical Diagnostics & Research industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Response Genetics and its competitors. Response Genetics's current Net Income From Continuing Operations is $-15.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Net Income From Continuing Operations of $-15.91 Mil. The current Net Income From Continuing Operations is $-15.91 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Net Income From Continuing Operations is $-15.91 Mil as of Jun. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc. was a molecular diagnostics company based in the United States that developed and sold biomarker-based tests and services for cancer care. It provided genomic information intended to help physicians personalize the diagnosis, monitoring, and treatment of cancer patients. The company operated through three service lines: Biopharma Services, Clinical Services, and Discovery Services, with Biopharma Services generating the majority of revenue. Biopharma offerings included molecular and biomarker testing, customized assay development, patient stratification, treatment selection, and clinical trial design consultation for pharmaceutical and biotechnology companies. Clinical Services supplied diagnostic testing to physicians and patients, while Discovery Services supported research. Response Genetics served customers in the United States and internationally, deriving most revenue domestically. The company filed for bankruptcy and its ticker later carried a Q suffix indicating Chapter 11 status.